Evaluation of oxidative stress, the activities of paraoxonase and arylesterase in patients with subclinical hypothyroidism

Journal of Investigative Medicine

Volumn 60, Issue 1, 2012, Pages 23-28

  Cebeci, Egemen ^a   Alibaz Oner, Fatm A ^b   Usta, Murat ^c   Yurdakul, Selen ^d   Erguney, Mecdi ^a  

^a HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

^c MINISTRY OF HEALTH   (Turkey)

^d FLORENCE NIGHTINGALE HOSPITAL   (Turkey)

Author keywords

Arylesterase; Atherosclerosis; Oxidative stress; Paraoxonase; Subclinical hypothyroidism

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; THYROTROPIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HYPOTHYROIDISM; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; OXIDATIVE STRESS;

EID: 84856710414     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31823581dd     Document Type: Article

References (41)

1. Canaris GJ, Manowitz NR, Major G, et al. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160: 526-534. (Pubitemid 30112276)
2. Zulewski H, Muller B, Exer P, et al. Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. J Clin Endocrinol Metab. 1997;82: 771-776. (Pubitemid 27106585)
3. Tanis BC, Westendorp RGJ, Smelt AHM. Effect of thyroid substitution on hypercholesterolemia in patients with subclinical hypothyroidism: a reanalysis of intervention studies. Clin Endocrinol. 1996;44: 643-649. (Pubitemid 26225179)
4. Kahaly GJ. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid. 2000;10: 665-679.
5. Panese MD, Ladenson PW, Meinert CL, et al. Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab. 2000;85: 2993-3001.
6. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991;286: 152-154.
7. Ekmekçi Ö, Donma O, Ekmek0i H. Paraoksonaz Cerrahpaza TNp Dergisi. 2004;35(2): 78-82.
8. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet. 1994;344: 1383-1389.
9. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21: 473-480. (Pubitemid 32323376)
10. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38: 1103-1111.
11. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004;37: 112-119. (Pubitemid 38077161)
12. Fatourechi V. Subclinical thyroid disease. Mayo Clin Proc. 2001;76: 413-416.
13. Tunbridge WMG, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinal. 1977;7: 481-493. (Pubitemid 8235965)
14. Geul KW, Sluisveld ILL, Grobbee DE, et al. The importance of thyroid microsomal antibodies in the development of elevated serum TSH in middle-aged women: association with serum lipids. Clin Endocrimal. 1993;39: 375-380.
15. Staub JJ, Althaus BU, Engler H, et al. Spectrum of subclinical and overt hypothyroidism: effect on thyrotrophin, prolactin and thyroid reverse, and metabolic impact on peripheral target tissues. Am J Med. 1992;92: 631-641.
16. Bindels AJ, Westendorp RG, Forlich M, et al. The prevalence of subclinical hypothyroidism at different total plasma cholesterol levels in middle aged men and women: a need far case-finding? Clin Endocrinol. 1999;50: 217-220. (Pubitemid 29100009)
17. Michalopoulous G, Alevizaki M, Piperingos G, et al. High serum cholesterol levels in persons with high normal TSH levels: should one extend the definition of subclinical hypothyroidism. Eur J Endocrinol. 1998;138: 141-145. (Pubitemid 28131089)
18. Bakler SJL, Ter Matten JC, Popp-Snijders C, et al. The relationship between thyrothropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab. 2001;86: 1206-1211. (Pubitemid 32323006)
19. Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocrine Rev. 2005;26: 704-728. (Pubitemid 41127279)
20. Fazio S, Palmieri EA, Lombardi G, et al. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res. 2004;59: 31-50. (Pubitemid 41327146)
21. Hak AE, Pols HAP, Visser TJ, et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000;132: 270-278. (Pubitemid 30106257)
22. Bazkol G, Atmaca H, TanrNverdi F, et al. Oxidative stress and enzymatic antioxidant status in patients with hypothyroidism before and after treatment. Exp Clin Endocrinol Diabetes. 2007;115(8): 522-526. (Pubitemid 350056765)
23. Durrington PN, Mackness B, Mackness MI. The hunt for nutritional and pharmacological modulators of paraoxonase [Editorial] Arterioscler. Thromb Vasc Biol. 2002;22: 1248-1250. (Pubitemid 34875730)
24. Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON1) is inactivated by oxidised low density lipoprotein and preserved by antioxidants. Free Radic Biol Med. 1999;26: 892-904. (Pubitemid 29198362)
25. Berliner JA, Navab M, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 1995;91: 2488-2496.
26. Navab M, Hama SY, Van Lenten BJ, et al. Mildly oxidized LDL induced an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. 1997;99: 2005-2020.
27. Ayub A, Mackness MI, Arrol S, et al. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol. 1999;19: 330-335. (Pubitemid 29072747)
28. Milionis HJ, Tambaki AB, Kanioglou CN, et al. Thyroid substitution therapy induced high-density lipoprotein-associated platelet-activating factor-acetylhydrolase in patient with subclinical hypothyroidism: a potential antiatherogenic effect. Thyroid. 2005;15(5): 455-460. (Pubitemid 40770625)
29. Azizi F, Raiszadeh F, Solati M, et al. Serum paraoxonase 1 activity is decreased in thyroid dysfunction. J Endocrinol Invest. 2003;26: 703-709. (Pubitemid 37441497)
30. Jayakumari N, Thejaseebai G. High prevalence of low serum paraoxonase-1 in subjects with coronary artery disease. J Clin Biochem Nutr. 2009;45(3): 278-284.
31. Şentürk T, Sarandol E, Gululu S, et al. Serum arylesterase activity is negatively correlated with inflammatory markers in patients with acute coronary syndromes. Saudi Med J. 2009;30(3): 334-339.
32. Coria MJ, Pastran AI, Gimenez MS. Serum oxidative stress parametres of women with hypothyroidism. Acta Biomed. 2009;80(2): 135-139.
33. Gamboa R, Regalado JC, Huesca-Gómez C, et al. Low paraoxonase and arylesterase plasma activities in Mexican patients with coronary artery disease. Arch Cardiol Mex. 2008;78(4): 360-368.
34. Fernandez V, Tapia G, Varela P, et al. Thyroid hormone-induced oxidative stress in rodents and humans: a comparative view and relation to redox regulation of gene expression. Comp Biochem Physiol C Toxicol Pharmacol. 2006;142: 231-239.
35. Resch U, Helsel G, Tatzber F, et al. Antioxidant status in thyroid dysfunction. Clin Chem Lab Med. 2002;40(11): 1132-1134. (Pubitemid 36024447)
36. Sarandöl E, Taz S, Dirican M, et al. Oxidative stress and serum paraoxonase activity in experimental hypothyroidism: effect of vitamin E supplementation. Cell Biochem Funct. 2005;23(1): 1-8. (Pubitemid 40068799)
37. Erdamar H, Demirci H, Yaman H, et al. The effect of hypothyroidism, hyperthyroidism, and their treatment on parameters of oxidative stress and antioxidant status. Clin Chem Lab Med. 2008;46(7): 1004-1010. (Pubitemid 352000488)
38. Venditti P, Balestrieri M, Di Meo S, et al. Effect of thyroid state on lipid peroxidation, antioxidant defenses, and susceptibility to oxidative stress in rat tissues. J Endocrinol. 1997;155(1): 151-157. (Pubitemid 27428316)
39. Torun AN, Kulaksizoǧlu S, Kulaksizoǧlu M, et al. Serum total antioxidant status an lipid peroxidation marker malondialdehyde levels in overt and subclinical hypothyroidism. Clin Endocrinol (Oxford). 2009;70(3): 469-474.
40. Imaizumi M, Akahoshi M, Ichimaru S, et al. Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab. 2004;89: 3365-3370. (Pubitemid 38951905)
41. Ichiki T. Thyroid hormone and atherosclerosis. Vascul Pharmacol. 2010;52(3-4): 151-156.